[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antibiotic-resistant-strain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antibiotic-resistant-strain":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,57,85,115,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100053455","phase-4-the-lalelalung-study-digital-stethoscope-clinical-evaluation-100053455",false,"NCT07631377","The LalelaLung Study: Digital Stethoscope Clinical Evaluation","LaLeLa","Inclusion Criteria:\n\n* Age 2 to 59 months at the time of screening\n* Presence of cough and\u002For difficulty breathing\n* No WHO-defined emergency\u002Fdanger signs (e.g., grunting, cyanosis, apnea, convulsions, or altered level of consciousness)\n* A legal caregiver is present, able to understand the study information, and willing to provide written informed consent\n* Caregiver is willing and able to provide contact information (e.g., mobile phone number) to allow 7-day follow-up after the clinic visit\n\nExclusion Criteria:\n\n* Presence of WHO-defined emergency signs requiring immediate referral or hospital admission (grunting, cyanosis, apnea, uncompensated shock, convulsions, diarrhea with severe dehydration, or altered level of consciousness)\n* Critical illness or clinical instability judged by the screening clinician or study physician to require urgent medical attention\n* Age outside the target range (younger than 2 months or older than 59 months)\n* Previous enrollment in the study\n* Refusal or withdrawal of informed consent by the legal caregiver at any time prior to randomization","ALL","2 Months","59 Months",{"count":20,"type":21},350,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Pneumonia is the leading infectious cause of death in children under five years of age worldwide, and most of these deaths occur in low- and middle-income countries. In these settings, frontline health workers diagnose pneumonia using the World Health Organization's Integrated Management of Childhood Illness (IMCI) guidelines, which rely mainly on counting how fast a child is breathing and checking for chest indrawing. This approach has saved many lives, but it is not very specific. As a result, many children who actually have self-limiting viral illnesses that do not require antibiotics are nonetheless treated with antibiotics, contributing to the global rise of antimicrobial resistance.\n\nNew digital stethoscopes paired with artificial intelligence (AI) can record a child's lung sounds and automatically detect abnormal sounds such as crackles and wheezes with accuracy comparable to physicians. The LaLeLa Lung Study will evaluate whether adding an AI-enabled digital stethoscope to standard IMCI assessment improves the accuracy of pneumonia diagnosis among children aged 2 to 59 months who present with cough and\u002For difficult breathing at a primary care clinic in Cape Town, South Africa.\n\nThe main component (Objective 1) is a randomized, triple-blinded diagnostic accuracy study that will enroll 350 children, randomly assigned in a 1:1 ratio to either IMCI care enhanced by the AI-enabled digital stethoscope or standard IMCI care. An independent panel of physicians, blinded to the AI results and to study-arm assignment, will review each case and serve as the reference standard for determining whether pneumonia was truly present. The investigators hypothesize that IMCI enhanced by the AI stethoscope will diagnose pneumonia more accurately, and target antibiotics more appropriately, than standard IMCI alone. Nested sub-studies will additionally evaluate a second AI stethoscope for tuberculosis detection, a wearable lung-sound and respiratory-rate patch, an automated respiratory-rate monitor, and a smartphone-connected pulse oximeter.\n\nA separate component (Objective 2) is a mixed-methods implementation study at a second clinic that will assess how easily health workers can use these devices, how acceptable the devices are to health workers and caregivers, and how well the devices fit into routine clinic workflows.\n\nThroughout the study, all AI-generated results will remain concealed from clinic staff, study clinicians, and caregivers, so the AI-generated results will not influence the care any child receives. All children continue to receive standard IMCI care. Findings will help inform whether AI-enabled digital auscultation should be integrated into childhood pneumonia care in South Africa and similar low-resource settings, with the goal of improving diagnosis, strengthening antibiotic stewardship, and reducing antimicrobial resistance and child mortality.",[27,28,29,30,31,32],"Pneumonia","Tuberculosis, Pulmonary","Respiratory Tract Infections","Bronchiolitis","Respiratory Sounds","Antibiotic Resistant Strain","NOT_YET_RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":21},"2026-08-17",{"date":41,"type":21},"2028-06-30",{"name":43,"class":44},"Johns Hopkins University","OTHER",{"id":46,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":48,"briefSummary":25,"conditions":49,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":56,"locationsCount":4},"100643415",{"count":20,"type":21},[24],[27,28,29,30,31,32],"2026-06-05",{"date":52,"type":37},"2026-06-09",{"date":54,"type":21},"2026-07-20",{"date":41,"type":21},{"name":43,"class":44},{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100536221","dynamics-of-amr-spread-persistence-and-evolution-between-humans-animals-and-their-environment-100536221","NCT06262009","Dynamics of AMR Spread, Persistence and Evolution Between Humans, Animals and Their Environment","Dyaspeo","Inclusion Criteria:\n\n* Adult or child planning to live in the same household as his\u002Fher dog during the three months following inclusion.\n* Planning to live in the same habitat in the next three months following inclusion (except for holidays).\n* Written consent of all adults and of at least one of the two parents for minors under parental authority. A different information note will be elaborated for each age category (6-10 yr-old, 10-15 yr-old and 16-18 yr-old).\n* Owning a dog recorded for a surgery at the National Veterinary School\n\nExclusion Criteria:\n\n* Lack of signed informed consent\n* Subject in alternating custody\n* Subject under legal protection (guardianship)\n* Subject deprived of liberty under judicial constraint\n* Subject undergoing psychiatric care\n* Lack of affiliation to a social security scheme\n* Volunteers who do not speak\u002Fwrite French",true,{"count":66,"type":21},525,"OBSERVATIONAL","Humans in contact with animals such as dog owners, may be at risk of antimicrobial resistance (AMR) acquisition. This is the central issue to be investigated in DYASPEO",[32,70],"Transmission, Close-Contact",[72,73],"antibiotic resistant transmission","transmission between dog and human","RECRUITING","2026-04-22",{"date":77,"type":37},"2026-04-23",{"date":79,"type":37},"2025-12-15",{"date":81,"type":21},"2029-03",{"name":83,"class":44},"Assistance Publique - Hôpitaux de Paris",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":64,"sex":16,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":84},"100397837","nasopharyngeal-carriage-of-s-pneumoniae-100397837","NCT04460313","Nasopharyngeal Carriage of S. Pneumoniae","Observatory of Streptococcus Pneumoniae Nasopharyngeal Carriage in Infants With Acute Otitis Media (AOM) and in Healthy Children\"","children seen on an outpatient\n\nInclusion Criteria:\n\n* both sexes\n* suffering from suppurative AOM or healthy children\n\n  * age: 6 months to 36 months for AOM\n  * age: 6 months to 15 years for healthy children\n* informed consent from parents or guardians\n* Children who haven't received antibiotic treatment within 7 days before enrollment,\n\nExclusion Criteria:\n\n* severe underlying disease,\n* inclusion in the study during the previous 12 months\n* Children with bullous myringitis cannot be included.","6 Months","15 Years",{"count":95,"type":21},25760,[97],"NA","This nasopharyngeal (NP) carriage surveillance study was requested by the European Agency for the Evaluation of Medicinal Products as a post-licensing commitment to determine whether the use of the pneumococcal conjugate vaccines (PCVs) including 7 then 13 valents (introduced in 2001 and 2010, respectively) caused a shift in the distribution of Streptococcus pneumoniae serotypes in children with acute otitis media and modified the resistance of this bacterial species to antibiotics.",[100,101,32],"Nasopharyngeal Carriage","Children, Only",[103,104,105],"Pneumococcal conjugate vaccine","Streptococcus pneumoniae","Carriage","2026-03-17",{"date":108,"type":37},"2026-03-19",{"date":110,"type":37},"2001-09-11",{"date":112,"type":21},"2026-12-31",{"name":114,"class":44},"Association Clinique Thérapeutique Infantile du val de Marne",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":123,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":135,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":84},"100593985","oritavancin-for-cied-infections-with-mdr-gram-positive-cocci-100593985","NCT07013552","Oritavancin for CIED Infections With MDR Gram-positive Cocci","Oritavancin as a Therapeutic Regimen for Cardiac Implantable Electronic Devices Infections With Multidrug-resistant Gram-positive Cocci","ORI-4-CIEDi","Inclusion Criteria:\n\n1. Completed 18 years of age\n2. Presence of signs and symptoms of superficial ABSSSI or PI in the form of a) redness\u002Fwarmth\u002Fswelling\u002Fpain or b) separation of the edges of the surgical incision with signs of inflammation or the need for repeated surgical debridement of the wound or c) the presence of decubitus of the skin and subcutaneous tissue in area of the generator or skin abscess\u002Ferosion of the device pocket, with purulent discharge from the wound or discharge giving a positive microbial culture\n3. Probable\u002F definite diagnosis of right-sided LRIE according to modified Dukes criteria (optional criterion)\n4. Suspected\u002Fconfirmed infection with drug-resistant Gram-positive cocci, i.e., Staphylococcus spp. (Stahphylococcus aureus or coagulase-negative staphylococci), Streptococcus spp. or Enterococcus spp. sensitive to oritavancin\n5. Suspected\u002Fconfirmed infection with Gram-positive cocci, i.e., Staphylococcus spp., Streptococcus spp., Enterococcus spp., sensitive to vancomycin or oritavancin and beta-lactam antibiotics in patients with a history of type I anaphylaxis to penicillin.\n\nExclusion Criteria:\n\n1. Suspected\u002Fconfirmed infection with Gram-positive or Gram-negative bacilli or anaerobic bacteria\n2. Suspected\u002Fconfirmed community-acquired infection or infection with Gram-positive cocci sensitive to betalactam antibiotics, including penicillin, ampicillin, or methicillin, based on empirical data or cultures (does not apply to patients with a history of type I anaphylaxis to penicillin)\n3. Confirmed resistance of Gram-positive cocci, which are the etiological factor of the infection, to vancomycin and oritavancin.\n4. History of hypersensitivity to oritavancin or another lipoglycopeptide antibiotic (applies to the experimental group only)\n5. History of hypersensitivity to vancomycin or another glycopeptide antibiotics (applies to the control group only)\n6. No possibility of temporarily interrupting\u002Finitiating alternative therapy to intravenous infusion of unfractionated heparin\n7. Pregnancy or breastfeeding\n8. Lack of informed written consent of the patient to participate in the study","18 Years",{"count":125,"type":21},100,[97],"The study aimed to conduct a randomized, non-inferiority controlled trial to compare the short- and medium-term efficacy and safety of two antibiotic dosage regimens in cardiac implantable electronic devices (CIED) infections with multidrug-resistant Gram-positive cocci: 1) single-dose therapy with a long-half-life antibiotic (oritavancin) vs. standard 7-14 days of therapy with a short-half-life antibiotic (vancomycin) for CIED surgical incision site or pocket infection; and 2) fractionated therapy with a long-half-life antibiotic (oritavancin) at seven-day intervals compared to standard therapy with a short-half-life antibiotic (vancomycin) fractionated in 2-3 daily doses in cases of lead-related infectious endocarditis.",[129,130,131,132,32,133,134],"Cardiac Implantable Electronic Device Infections","Infective Endocarditis","Multidrug-resistant Bacteria Screening","Gram Positive Bacterial Infection","Antibiotic Therapy","Healthcare Associated Infections",[136,137,138,139,140,141],"Cardiac implantable electronic device","Gram-positive cocci","Health-care associated infections","Lead-related infective endocarditis","Multidrug-resistant bacteria","Pocket infection","2025-06-02",{"date":144,"type":37},"2025-06-10",{"date":146,"type":21},"2025-06",{"date":148,"type":21},"2026-10",{"name":150,"class":44},"Medical University of Silesia",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":123,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":84},"100560937","antimicrobial-therapeutic-drug-monitoring-during-lung-transplant-perioperative-phase-100560937","NCT06583642","Antimicrobial Therapeutic Drug Monitoring During Lung Transplant Perioperative Phase","Inclusion Criteria:\n\n* Recipient of LUTX\n* Age \\> 18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Already undergone LUTX\n* Documented respiratory colonization in the 12 months preceding LUTX\n* Undergoing any antimicrobial therapy preceding LUTX\n* Documented post-LUTX endobronchial plasma leak requiring high levels of PEEP \\> 15 cmH2O.",{"count":158,"type":21},20,"Background: Post-LUTX pneumonia represents a leading cause of death along the first month after LUTX. Donor-derived transmission of pathogenic species occurs up to 25% of recipients receiving a graft with a positive BAL culture, despite in-vitro adequate antimicrobial prophylaxis.\n\nHypothesis: LUTX recipients are either exposed to suboptimal antimicrobial doses or antimicrobial penetration into the lug parenchyma is altered either due to surgery (absence of bronchial anastomoses) or to the hyperinflammatory state.\n\nMethods: LUTX recipients admitted to the intensive care unit at the Fondazione IRCCS Ca' Granda Policlinico Hospital. According to the institutional perioperative prophylaxis protocol and the donor\u002Frecipient ecology the most frequent antimicrobial molecules administered will be: cefepime, vancomycin, and meropenem. Antimicrobial pharmacokinetics will be investigated at three timepoints. Plasma levels of the ongoing antimicrobial molecule will be assessed at ICU admission, on postoperative day 1 and on postoperative day 3. Bronchoalveolar lavage (BAL) samples for the measurement of BAL antimicrobial levels will be collected during the BAL performed for clinical indication on postoperative day 1 and on postoperative day 3.\n\nAbsolute plasma and BAL antimicrobial levels will be assessed. The ratio of BAL to plasma dosage of antimicrobial will be assessed to evaluate antimicrobial penetration within the target tissue. Correlation between both plasma and BAL antimicrobial dosage and recipients' postoperative fluid balance, body weight, vasopressor requirement, renal function will be performed.",[161,162,32],"Lung Transplant Infection","Pneumonia, Bacterial","2025-05-19",{"date":165,"type":37},"2025-05-22",{"date":167,"type":21},"2025-07-01",{"date":169,"type":21},"2027-03-01",{"name":171,"class":44},"Policlinico Hospital"]